

# Magnesium sulphate for the prevention of supra-ventricular dysrhythmia following non-cardiac thoracic surgery

<b>Submission date</b> 11/06/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 18/07/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 22/08/2013	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Roger Stedman

**Contact details**  
2nd Floor  
Lincoln House  
Heartlands Hospital  
Bordesley Green East  
Birmingham  
United Kingdom  
B5 5SS

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
2004-002818-11

**Protocol serial number**  
Version 5

## Study information

## **Scientific Title**

### **Acronym**

MAGNETS

### **Study objectives**

The prophylactic perioperative correction of magnesium deficiency by infusion of magnesium sulphate to all patients presenting for thoracotomy or thoracotomy for pneumonectomy, lobectomy or oesophagectomy will significantly reduce the incidence of supra-ventricular dysrhythmias post operatively.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

South Birmingham Research Ethics Committee. Date of approval: 04/05/2005 (ref: 05/Q2707/1)

### **Study design**

Single-centre prospective double-blind randomised placebo-controlled study

### **Primary study design**

Interventional

### **Study type(s)**

Prevention

### **Health condition(s) or problem(s) studied**

Supra-ventricular dysrhythmias in patients following non-cardiac thoracic surgery

### **Interventions**

Patients are randomised into either the placebo or magnesium groups. Patients receive either placebo or 5 g magnesium sulphate infusion intra-operatively, day 1 and day 2 post-operatively. Continuous electrocardiogram (ECG) recording for 5 days will be commenced using a holter (non-invasive) recorder after induction of anaesthesia. ECG data will be analysed by a cardiac physiologist who is blinded from which treatment group the patient is in.

### **Intervention Type**

Drug

### **Phase**

Not Specified

### **Drug/device/biological/vaccine name(s)**

Magnesium sulphate

### **Primary outcome(s)**

To demonstrate a clinically and statistically significant reduction in the incidence of postoperative supra-ventricular dysrhythmias in the patient group who have received magnesium in comparison to the placebo group. It is aimed that patients have holter monitoring for 5 days post-operatively.

**Key secondary outcome(s)**

1. Length of hospital stay
2. Thirty-day mortality

**Completion date**

30/06/2008

**Eligibility****Key inclusion criteria**

1. Both male and female patients
2. Above 18 years; no upper age limit
3. Patients presenting to the Department of Thoracic Surgery at Birmingham Heartlands Hospital for elective lobectomy, bi-lobectomy, pneumonectomy or oesophagectomy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Evidence of renal failure (serum creatinine of >130)
2. Liver failure
3. Pre-existing cardiac arrhythmia
4. Undergoing long-term treatment for an arrhythmia
5. On long-term treatment with nifedipine or aminoglycosides
6. Known hypersensitivity to magnesium sulphate
7. If preoperative magnesium level is equal or greater than 1.2 mmol/l
8. If they are unwilling or unable to give informed consent for their participation or if they withdraw consent
9. Patients who have participated in another interventional study within the previous 3 months

**Date of first enrolment**

01/06/2006

**Date of final enrolment**

30/06/2008

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

2nd Floor

Birmingham

United Kingdom

B5 5SS

## Sponsor information

**Organisation**

Heart of England NHS Foundation Trust (UK)

## Funder(s)

**Funder type**

Charity

**Funder Name**

British Heart Foundation (UK)

**Alternative Name(s)**

The British Heart Foundation, the\_bhf, BHF

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Trusts, charities, foundations (both public and private)

**Location**

United Kingdom

**Funder Name**

European Association of Cardiothoracic Anaesthesiologists (EACTA) (Ireland)

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2011		Yes	No